| Outcome Measures: |
Primary: Participant invited to consent and consented via e-signature (Yes/No), Measured as count of participants., During Screening (Week -2 to week 0 )|Participant with at least 70% unblinded CGM (continuous glucose monitoring) data (Yes/No), Measured as Count of participants., From time of first unblinded CGM measurement until 10 weeks after the time of first unblinded CGM measurement|Participant completion of questionnaires and per protocol planned remote visits (RVs), % of questionnaires and RVs completed., From week 0 until end of study (week 12) | Secondary: Time in range (TIR) (3.9-10 mmol/L), % of time., From time of first unblinded CGM measurement (week 2) until time of last unblinded CGM measurement (week 12)|Time above range (TAR) (above 10 mmol/L), % of time., From time of first unblinded CGM measurement (week 2) until time of last unblinded CGM measurement (week 12)|Time below range (TBR) L1 (3.0-3.9 mmol/L), % of time., From time of first unblinded CGM measurement (week 2) until time of last unblinded CGM measurement (week 12)|Time below range (TBR) L2 (below 3.0 mmol/L), % of time., From time of first unblinded CGM measurement (week 2) until time of last unblinded CGM measurement (week 12)|Mean glucose, nmol/L., From time of first unblinded CGM measurement (week 2) until time of last unblinded CGM measurement (week 12)|Coefficient of variation (CV) of glucose measurements, From time of first unblinded CGM measurement (week 2) until time of last unblinded CGM measurement (week 12)|Participant with at least 70% heart rate (pulse) data (Yes/No), Count of participants., From time of first heart rate measurement (week 0) until 12 weeks after the time of first heart rate measurement
|
